Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis

• Main Authors: Eugenia Veronica Di Brizzi (Author), Dario Buononato (Author), Pierfrancesco Benvenuto (Author), Giuseppe Argenziano (Author), Rocco De Pasquale (Author), Carmen Silvia Fiorella (Author), Claudia Gioffrè (Author), Maria Letizia Musumeci (Author), Giovanni Palazzo (Author), Leonardo Zichichi (Author), Anna Balato (Author)
• Format: Book
• Published: Mattioli1885, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis. Objectives: This study aimed to evaluate the effectiveness, safety and survival of t...